Cognoa
Cognoa is an early childhood development and pediatric behavioral health company that develops digital diagnostics and therapeutics aimed at enabling earlier and more equitable access to care for children and families. Their flagship product, Canvas Dx, is the first FDA-authorized diagnostic solution for autism, allowing clinicians to diagnose or rule out autism in children aged 1.5 to 6 years within days. By leveraging AI and a whole-child approach, Cognoa addresses significant delays in autism diagnosis, which can average over three years, and aims to improve outcomes for underserved populations. The company is positioned to transform pediatric healthcare with innovative technology and has gained traction with reimbursement from Highmark Insurance for their diagnostic tool.
Cognoa
Cognoa is an early childhood development and pediatric behavioral health company that develops digital diagnostics and therapeutics aimed at enabling earlier and more equitable access to care for children and families. Their flagship product, Canvas Dx, is the first FDA-authorized diagnostic solution for autism, allowing clinicians to diagnose or rule out autism in children aged 1.5 to 6 years within days. By leveraging AI and a whole-child approach, Cognoa addresses significant delays in autism diagnosis, which can average over three years, and aims to improve outcomes for underserved populations. The company is positioned to transform pediatric healthcare with innovative technology and has gained traction with reimbursement from Highmark Insurance for their diagnostic tool.